Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis

American Journal of Gastroenterology

Volumn 94, Issue 4, 1999, Pages 1012-1017

  Lin, Han Chieh ^a   Hou, Ming Chih ^b   Lee, Wui Chiang ^a   Huang, Yi Tsau ^b   Lee, Fa Yauh ^a   Chang, Full Young ^b   Tsai, Yang Te ^a   Lee, Shou Dong ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD OXYGENATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; TISSUE OXYGENATION; VIRUS INFECTION;

AGED; HEMODYNAMIC PROCESSES; HEPATITIS B; HEPATITIS C; HORMONES; HUMANS; INFUSIONS, INTRAVENOUS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OCTREOTIDE; OXYGEN CONSUMPTION; PULMONARY CIRCULATION;

EID: 0033119937     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00060-X     Document Type: Article

References (46)

1. Braillon A, Cales P, Valla D, et al. Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut 1986:27:1204-9.
2. Meng HC, Lin HC, Tsai YT, et al. Relationship between the severity of cirrhosis and haemodynamic values in patients with cirrhosis. J Gastroenterol Hepatol 1994;9:148-53.
3. Lebrec D. Pharmacological treatment of portal hypertension: Hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994;61:65-107.
4. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sei 1982;31:1133-40.
5. Hvvang SJ, Lin HC, Chang CF, et al. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol 1992:16:320-5.
6. Sung JJY, Chung SCS, Lai CW, et al. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet 1993:342:637-41.
7. Eriksson LS, Brundin T, Söderlund C, et al. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919-25.
8. McCormick PA, Dick R, Siringo S, et al. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990;2:489-92.
9. Lin HC, Tsai YT, Lee FY, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992;103:229-34.
10. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension. A double-blind, placebo-controlled study. Hepatology 1992;16:1180-6.
11. Lin HC, Tsai YT, Huang CC, et al. Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. J Hepatol 1994;21:424-9.
12. Buonamico P, Sabba C, Garcia-Tsao G, et al. Octreotideblunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-Doppler study. Hepatology 1995:21:134-9.
13. Lin HC, Tsai YT, Yang MCM, et al. Effect of octreotide on total effective vascular compliance in patients with posthepatitic cirrhosis. J Hepatol 1996;24:81-7.
14. Lin HC, Tsai YT, Lee SD, et al. Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigenpositive cirrhosis. Clin Pharmacol Ther 1992;52:134-8.
15. Ottesen LH, Flyvbjerg A, Møller S, et al. The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. Aliment Pharmacol Ther 1998;12:657-65.
16. Merkel C, Gatta A, Zuin R, et al. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985;32:92-8.
17. Kleber G, Sauerbruch T, Fischer G, et al. Somatostatin does not reduce oesophageal variceal pressure in liver cirrhosis. Gut 1988;29:153-6.
18. Gines A, Salmeron JM, Gines P, et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992;103: 1868-74.
19. Pringle SD, McKee RF, Garden OJ, et al. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988;2: 451-9.
20. Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, et al. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompcnsated cirrhosis. Nephrol Dial Transplant 1988;3:604-7.
21. Zironi G, Rossi C, Siringo S, et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: A double-blind, controlled study. Liver 1996; 16: 225-34.
22. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology 1981;80:518-25,
23. Naeije R, Hallemans R, Mols P, et al. Effects of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. Crit Care Med 1982;10:578-82.
24. McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995:21:1255-60.
25. Gaudin C, Moreau R, Champigneulle B, et al. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995;15:236-41.
26. Cirera I, Feu F, Luca A, et ai. Effects of bolus injection and continuous infusion of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation. Hepatology 1995;22:106-11.
27. M011er S, Brinch K, Henriksen JH, et al. Effect of octreotide on systemic, central and splanchnic haemodynamics in cirrhosis. J Hepatol 1997;26:1026-33.
28. Krowka MJ, Cortese DA. Pulmonary aspects of chronic liver disease and liver transplantation. Mayo Clin Proc 1985;60: 407-18.
29. Moreau R, Lee SS, Soupison T, et al. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J Hepatol 1988;7:98-105.
30. Moreau R, Lee SS, Hadengue A, et al. Relationship between oxygen transport and oxygen uptake in patients with cirrhosis: Effects of vasoactive drugs. Hepatology 1989;9:427-32.
31. Moreau R, Roulot D, Braillon A, et al. Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: Evidence for an impaired cardiopulmonary baroreflex function. Hepatology 1989; 10:93-7.
32. Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981;27:213-8.
33. Pugh RNH, Murray-Lyon M, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
34. Forrester JS, Ganz W, Diamond G, et al. Thermodilution cardiac output determination with a single flow-directed catheter. Am Heart J 1972;83:306-11.
35. Ottsen LH, Flyvbjerg A, Jakobsen P, et al. The pharmacoki-netics of octreotide in cirrhosis and in healthy man. J Hepatol 1997:26:1018-25.
36. Soderman C, Juhlin-Dannfelt A, Lagerstrand L, et al. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 1994:21:52-7.
37. + retention in portal hypertensive rats. Gastroenterology 1993:104:575-9.
38. Brent BN, Matthay RA, Mahler DA, et al. Relationship between oxygen uptake and oxygen transport in stable patients with chronic obstructive pulmonary disease. Physiologic effects of nitroprusside and hydralazine. Am Rev Respir Dis 1984:129:682-6.
39. Plusczky T, Rathgeb D, Westermann S, et al. Effects of somatostatin (SMS) on pancreatic microcirculation. Dig Dis Sei 1997:42:2254-63.
40. Pizcueta MP, Garcia-Pagan JC, Fernandez M, et al. Glucagon hinders the effects of somatostatin on portal hypertension: A study in rats with partial portal vein ligation. Gastroenterology 1991:101:1710-5.
41. Lin HC, Yang MCM, Hou MC, et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996;23:537-43.
42. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol 1992;262:G274-7.
43. Li Y, Owyang C. Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 1993;265: G251-7.
44. Webb SC, Krikler DM, Hendry WG, et al. Electrophysiological actions of somatostatin on the atrioventricular junction in sinus rhythm and reentry tachycardia. Br Heart J 1986;56: 236-41.
45. Franco-Cerceda A, Bengtsson L, Lundburg JM. Inotropic effects of calcitonin gene-related peptide, vasoactive intestinal polypeptide and somatostatin on the human right atrium in vitro. Eur J Pharmacol 1987;134:69-76.
46. Hou ZY, Lin CI, Chiu TH, et al. Somatostatin effects in isolated human atrial fiber. J Mol Cell Cardiol 1987;19:17785.